News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Bristol-Myers Squibb Company (BMY) Recalls Vials of Cancer Drug

8/31/2012 6:43:45 AM

PRINCETON, N.J., August 30, 2012 - Bristol-Myers Squibb Company (NYSE: BMY) has initiated a voluntary recall nationwide of 10 lots of BiCNU® (carmustine for injection) previously manufactured by Ben Venue Laboratories, Inc., a former, third-party contract manufacturer for the company, to the user level. The precautionary recall of BiCNU, a chemotherapeutic agent administered to patients in a hospital or other clinical setting, is being initiated following the discovery of one overfilled vial of BiCNU during routine testing. An overfilled vial of BiCNU represents a significant risk to patients due to the nature of product administration and could result in patients receiving a dose greater than prescribed. There have been no reported adverse events associated with this issue.

BiCNU is used as a therapy for treatment of brain tumors, multiple myeloma, Hodgkin’s disease and non- Hodgkin’s lymphoma. Potential adverse events include myelosuppression, pulmonary toxicity and renal abnormality, as well as increased incidence of other adverse events known to be caused by carmustine. In the Hematopoietic Stem Cell Transplantation (HSCT) setting, which has been reported as an off-label use, BiCNU is administered using a high dose regimen and this may lead to fatal outcomes in certain individuals.

This recall is being conducted in the U.S., Canada and countries within Europe, Latin America and Asia-Pacific for lots previously manufactured by Ben Venue. Bristol-Myers Squibb does not anticipate a product shortage resulting from the recall as current supply is secured through another manufacturer.

Bristol-Myers Squibb is committed to ensuring patient safety and is working to resolve this issue quickly and appropriately. The company is notifying regulatory authorities in impacted countries and is issuing recall communications to hospitals and health care professionals who may have received product from recalled lots.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program online, by regular mail, or by fax.

Online: Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: Mail to address on the pre-addressed form. Fax: 1-800-FDA-0178

This recall is for the following lots of BiCNU distributed between March 2010 and July 2011. Hospitals and health care professionals who have received the indicated lots are directed to cease use immediately and contact the Bristol-Myers Squibb Company recall coordinator to arrange return of all remaining inventory.

Read at
Read at Nasdaq
Read at Sacramento Bee
Read at Washington Post
Read at

comments powered by Disqus